Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 14

Russian guidelines for the management of COPD: algorithm of pharmacologic treatment [Corrigendum]

Authors Aisanov Z , Avdeev S , Arkhipov V, Belevskiy A , Chuchalin A, Leshchenko I , Ovcharenko S , Shmelev E , Miravitlles M 

Received 13 November 2018

Accepted for publication 13 November 2018

Published 18 January 2019 Volume 2019:14 Pages 243—244


Aisanov Z, Avdeev S, Arkhipov V, Belevskiy A, Chuchalin A, Leshchenko I, Ovcharenko S, Shmelev E, Miravitlles M. Int J Chron Obstruct Pulmon Dis. 2018;13:183–187.

Page 186, Disclosure, the text “The authors report no conflicts of interest in this work” should read “SA has received speaker/consultancy fees from Boehringer Ingelheim, AstraZeneca, Chiesi, Teva and Novartis; non-financial support from Boehringer Ingelheim, Chiesi and Novartis; and research grants from AstraZeneca, GlaxoSmithKline and Novartis. MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL Behring, Grifols and Novartis; consultancy fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Mereo BioPharm, Verona Pharma, pH Pharma, Novartis and Grifols; and research grants from GlaxoSmithKline and Grifols. ZA has received speaker/consultancy fees from Boehringer Ingelheim, AstraZeneca, Chiesi, Teva and Novartis, GlaxoSmithKline; non-financial support from Boehringer Ingelheim, GSK and Novartis; and research grants from AstraZeneca, GlaxoSmithKline and Novartis. The authors report no other conflicts of interest in this work”.

Read the original article

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.